ZUO LI YAO YE(300181)2025-03-11 12:52Group 1: Market Strategy and Product Promotion - The company will leverage core products like Wuling Capsules and Bailing Capsules to enhance hospital coverage and penetrate deeper into lower-tier cities and community health service centers [2][3] - The company aims to strengthen its OTC market presence by enhancing brand planning and conducting various promotional activities to improve patient education and product awareness [3][4] - A strategic partnership with Baidu Health has been established to enhance digital marketing and patient education, facilitating better service experiences for patients [5][6] Group 2: Sales Performance and Growth Projections - Bailing Capsules, launched in December 2024, is expected to capitalize on the recent procurement results to expand market presence through self-operated and agency-driven models [4] - Lingze Tablets are projected to see a sales volume and revenue increase of 23.17% and 22.64% respectively in 2024 compared to the previous year [6] - Linglianhua Granules, targeting middle-aged women, has achieved an exposure of 180 million and over 250,000 potential patient interactions since its online launch in July 2024 [6] Group 3: Financial Outlook and Shareholder Returns - The company proposes a cash dividend of RMB 6.00 per 10 shares for 2024, maintaining a high dividend payout rate [7][8] - Estimated stock incentive expenses for 2025 are projected to be around RMB 30 million [8]